The American firm hopes to obtain marketing authorization for its candidate vaccine against RSV, the virus that causes bronchiolitis, by the fall. In Puurs, investments are planned so that the Belgian production plant can continue to keep pace.
By Anne-Sophie Leurquin
After having achieved 100 billion dollars in turnover in 2022 (57% of which thanks to its vaccines against covid), the American Big Pharma is reinvesting its dividends. It has just bought out the American biotech Seagen, which specializes in the research and development of cancer treatments for an amount of 43 billion dollars (40.1 billion euros). At the end of December, the American firm also announced an investment of 1.2 billion over three years for its Belgian site in Puurs, which employs 4,500 people.
With this offer, enjoy:
-
Unlimited access to all the articles, files and reports of the editorial staff -
The newspaper in digital version -
Reading comfort with limited advertising
